These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24132143)

  • 1. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
    Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
    Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
    Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
    Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
    Migita T; Narita T; Nomura K; Miyagi E; Inazuka F; Matsuura M; Ushijima M; Mashima T; Seimiya H; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y
    Cancer Res; 2008 Oct; 68(20):8547-54. PubMed ID: 18922930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
    Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
    BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms.
    Zaidi N; Royaux I; Swinnen JV; Smans K
    Mol Cancer Ther; 2012 Sep; 11(9):1925-35. PubMed ID: 22718913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
    Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
    Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Topoisomerase I mutations are associated with resistance to camptothecin.
    Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
    Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway.
    Lee JH; Jang H; Lee SM; Lee JE; Choi J; Kim TW; Cho EJ; Youn HD
    FEBS J; 2015 Jan; 282(2):361-71. PubMed ID: 25367309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
    Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
    BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
    Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
    Xin M; Qiao Z; Li J; Liu J; Song S; Zhao X; Miao P; Tang T; Wang L; Liu W; Yang X; Dai K; Huang G
    Oncotarget; 2016 Jul; 7(28):44252-44265. PubMed ID: 27317765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
    Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
    Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
    Migita T; Okabe S; Ikeda K; Igarashi S; Sugawara S; Tomida A; Soga T; Taguchi R; Seimiya H
    Int J Cancer; 2014 Jul; 135(1):37-47. PubMed ID: 24310723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.